Loading...

We've got a brand new version of Simply Wall St! Try it out

Paradigm Biopharmaceuticals

ASX:PAR
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PAR
ASX
A$611M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. The last earnings update was 80 days ago. More info.


Add to Portfolio Compare Print
  • Paradigm Biopharmaceuticals has significant price volatility in the past 3 months.
PAR Share Price and Events
7 Day Returns
12.4%
ASX:PAR
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
281.8%
ASX:PAR
50.9%
AU Biotechs
16.3%
AU Market
PAR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Paradigm Biopharmaceuticals (PAR) 12.4% 27.3% 129.4% 281.8% 646.7% -
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • PAR outperformed the Biotechs industry which returned 50.9% over the past year.
  • PAR outperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
PAR
Industry
5yr Volatility vs Market

Value

 Is Paradigm Biopharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Paradigm Biopharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is A$3.36.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Paradigm Biopharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Paradigm Biopharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:PAR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$-0.11
ASX:PAR Share Price ** ASX (2019-11-18) in AUD A$3.36
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Paradigm Biopharmaceuticals.

ASX:PAR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:PAR Share Price ÷ EPS (both in AUD)

= 3.36 ÷ -0.11

-30.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Paradigm Biopharmaceuticals is loss making, we can't compare its value to the Global Biotechs industry average.
  • Paradigm Biopharmaceuticals is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Paradigm Biopharmaceuticals's expected growth come at a high price?
Raw Data
ASX:PAR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -30.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-28%per year
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Paradigm Biopharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Paradigm Biopharmaceuticals's assets?
Raw Data
ASX:PAR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.43
ASX:PAR Share Price * ASX (2019-11-18) in AUD A$3.36
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:PAR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:PAR Share Price ÷ Book Value per Share (both in AUD)

= 3.36 ÷ 0.43

7.8x

* Primary Listing of Paradigm Biopharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Paradigm Biopharmaceuticals is overvalued based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Paradigm Biopharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Paradigm Biopharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Paradigm Biopharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-28%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Paradigm Biopharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Paradigm Biopharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Paradigm Biopharmaceuticals's earnings growth to the Australia market average as it is expected to be loss making during the next 1-3 years.
  • Paradigm Biopharmaceuticals's revenue growth is positive but not above the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:PAR Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:PAR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -28%
ASX:PAR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 0.2%
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:PAR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:PAR Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-06-30 3 -28 -28 1
2021-06-30 3 -27 -27 1
2020-06-30 3 -8 -8 1
2019-11-18
ASX:PAR Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 3 -6 -16
2019-03-31 3 -7 -11
2018-12-31 3 -7 -7
2018-09-30 3 -6 -7
2018-06-30 3 -6 -6
2018-03-31 2 -4 -6
2017-12-31 2 -3 -5
2017-09-30 2 -4 -5
2017-06-30 2 -4 -4
2017-03-31 2 -5 -4
2016-12-31 1 -6 -4
2016-09-30 1 -5 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Paradigm Biopharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Paradigm Biopharmaceuticals's revenue is expected to grow by 0.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:PAR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Paradigm Biopharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:PAR Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-06-30 -0.15 -0.15 -0.15 1.00
2021-06-30 -0.14 -0.14 -0.14 1.00
2020-06-30 -0.04 -0.04 -0.04 1.00
2019-11-18
ASX:PAR Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 -0.11
2019-03-31 -0.08
2018-12-31 -0.06
2018-09-30 -0.06
2018-06-30 -0.05
2018-03-31 -0.05
2017-12-31 -0.05
2017-09-30 -0.04
2017-06-30 -0.04
2017-03-31 -0.05
2016-12-31 -0.05
2016-09-30 -0.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Paradigm Biopharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Paradigm Biopharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Paradigm Biopharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Paradigm Biopharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Paradigm Biopharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Paradigm Biopharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Paradigm Biopharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Paradigm Biopharmaceuticals's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Paradigm Biopharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Paradigm Biopharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:PAR Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 2.98 -15.63 3.83 7.90
2019-03-31 2.84 -11.32 3.23 7.49
2018-12-31 2.69 -7.02 2.68 7.07
2018-09-30 2.69 -6.60 2.51 6.83
2018-06-30 2.68 -6.19 2.27 6.59
2018-03-31 2.24 -5.61 1.95 5.91
2017-12-31 1.79 -5.03 1.62 5.22
2017-09-30 1.81 -4.65 1.76 4.73
2017-06-30 1.82 -4.28 1.89 4.23
2017-03-31 1.56 -4.30 1.97 3.94
2016-12-31 1.30 -4.32 2.05 3.65
2016-09-30 1.30 -3.62 1.74 3.26
2016-06-30 1.29 -2.92 1.42 2.87
2016-03-31 0.67 -2.91 1.65 1.96
2015-12-31 0.05 -2.38 1.37 1.06
2015-09-30 0.02 -1.97 1.39 0.61
2015-06-30 -1.57 1.41 0.16
2014-06-30 -0.23 0.23

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Paradigm Biopharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Paradigm Biopharmaceuticals has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Paradigm Biopharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Paradigm Biopharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Paradigm Biopharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Paradigm Biopharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Paradigm Biopharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Paradigm Biopharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Paradigm Biopharmaceuticals has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Paradigm Biopharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2254.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Paradigm Biopharmaceuticals Company Filings, last reported 4 months ago.

ASX:PAR Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 82.81 0.04 78.84
2019-03-31 82.81 0.04 78.84
2018-12-31 19.36 0.00 9.93
2018-09-30 19.36 0.00 9.93
2018-06-30 13.86 0.04 2.45
2018-03-31 13.86 0.04 2.45
2017-12-31 14.92 0.00 6.00
2017-09-30 14.92 0.00 6.00
2017-06-30 13.39 0.04 2.59
2017-03-31 13.39 0.04 2.59
2016-12-31 14.71 0.00 5.02
2016-09-30 14.71 0.00 5.02
2016-06-30 11.23 0.04 3.00
2016-03-31 11.23 0.04 3.00
2015-12-31 12.68 0.04 5.27
2015-09-30 12.68 0.04 5.27
2015-06-30 0.61 0.17 0.12
2014-06-30 -0.15 0.20 0.01
  • Paradigm Biopharmaceuticals's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Paradigm Biopharmaceuticals had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Paradigm Biopharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • Paradigm Biopharmaceuticals has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 3.9% each year.
X
Financial health checks
We assess Paradigm Biopharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Paradigm Biopharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Paradigm Biopharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Paradigm Biopharmaceuticals dividends.
If you bought A$2,000 of Paradigm Biopharmaceuticals shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Paradigm Biopharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Paradigm Biopharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:PAR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:PAR Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2022-06-30
2021-06-30
2020-06-30
2019-11-18

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Paradigm Biopharmaceuticals has not reported any payouts.
  • Unable to verify if Paradigm Biopharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Paradigm Biopharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Paradigm Biopharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Paradigm Biopharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Paradigm Biopharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Paradigm Biopharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Paradigm Biopharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paul Rennie
COMPENSATION A$1,067,388
AGE 60
CEO Bio

Mr. Paul Rennie, BSc, MBM, Grad Dip Commercial Law, MSTC, has been an Executive Director of Paradigm BioPharmaceuticals Ltd. since May 2, 2014 and serves as its Chief Executive Officer and Managing Director. Mr. Rennie served as Special Projects Consulatnat at Mesoblast Limited. He served as Vice President of Special Projects at Mesoblast Limited. He served as the Chief Operating Officer and Senior Vice President of Operations at Mesoblast Limited and also served as its Special Projects Consultant since May 12, 2008. Mr. Rennie has over 25 years experience in marketing and business development within the Australian biomedical and pharmaceutical industry. He served as Chief Operating Officer of Mesoblast Ltd. He served as Director of Business Development for Soltec, a wholly owned subsidiary of F H Faulding & Co., Ltd., with focus on developing improved pharmaceutical drug delivery systems. Previously, as Business Development Manager for the Biosciences Division of Bonlac, he led the commercialisation strategies and licensing negotiations between Bonlac's CPP-ACP technology to Warner Lambert. From 1990 to 1994 he held various positions with the global pharmaceutical company Merck Ltd., where as National Sales and Marketing Manager he was responsible for Australia-wide sales of pharmaceuticals, analytical reagents, environmental monitoring products and scientific research products. In this capacity, Mr. Rennie implemented a new strategic plan which contributed to transforming Merck Australia from having a loss in 1993 to record sales and profits in 1996.

CEO Compensation
  • Paul's compensation has increased whilst company is loss making.
  • Paul's remuneration is about average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Paradigm Biopharmaceuticals management team in years:

4.2
Average Tenure
  • The tenure for the Paradigm Biopharmaceuticals management team is about average.
Management Team

Paul Rennie

TITLE
CEO, MD & Executive Director
COMPENSATION
A$1M
AGE
60

Kevin Hollingsworth

TITLE
CFO & Company Secretary
COMPENSATION
A$60K
AGE
66
TENURE
5.5 yrs

Claire Kaufman

TITLE
Chief Operations Officer
TENURE
4.2 yrs

Ravi Krishnan

TITLE
Chief Scientific Officer
TENURE
4.2 yrs
Board of Directors Tenure

Average tenure and age of the Paradigm Biopharmaceuticals board of directors in years:

5.3
Average Tenure
68
Average Age
  • The tenure for the Paradigm Biopharmaceuticals board of directors is about average.
Board of Directors

Graeme Kaufman

TITLE
Non-Executive Chairman
COMPENSATION
A$120K
AGE
70
TENURE
5.5 yrs

Paul Rennie

TITLE
CEO, MD & Executive Director
COMPENSATION
A$1M
AGE
60
TENURE
5.5 yrs

Chris Fullerton

TITLE
Independent Non-Executive Director
COMPENSATION
A$60K
AGE
68
TENURE
5.2 yrs

John Gaffney

TITLE
Independent Non-Executive Director
COMPENSATION
A$60K
TENURE
5.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
02. Jul 19 Buy Christopher Fullerton Individual 27. Jun 19 27. Jun 19 10,000 A$1.48 A$14,840
01. Jul 19 Buy Paul Rennie Individual 28. Jun 19 28. Jun 19 35,000 A$1.40 A$49,000
23. Apr 19 Buy Christopher Fullerton Individual 23. Apr 19 23. Apr 19 19,500 A$1.65 A$32,130
08. Mar 19 Buy Christopher Fullerton Individual 04. Mar 19 04. Mar 19 100,000 A$1.18 A$118,116
13. Dec 18 Buy Paul Rennie Individual 30. Nov 18 13. Dec 18 480,392 A$0.69 A$201,087
X
Management checks
We assess Paradigm Biopharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Paradigm Biopharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is Paradigm Biopharmaceuticals Limited's (ASX:PAR) CEO Overpaid Relative To Its Peers?

View our latest analysis for Paradigm Biopharmaceuticals How Does Paul Rennie's Compensation Compare With Similar Sized Companies? … Our data indicates that Paradigm Biopharmaceuticals Limited is worth AU$261m, and total annual CEO compensation is AU$573k. … ASX:PAR CEO Compensation, August 28th 2019 Is Paradigm Biopharmaceuticals Limited Growing?

Simply Wall St -

What Kind Of Shareholders Own Paradigm Biopharmaceuticals Limited (ASX:PAR)?

Insider Ownership Of Paradigm Biopharmaceuticals The definition of an insider can differ slightly between different countries, but members of the board of directors always count. … General Public Ownership The general public -- mostly retail investors -- own 67% of Paradigm Biopharmaceuticals. … Private Company Ownership We can see that Private Companies own 11%, of the shares on issue.

Simply Wall St -

Can You Imagine How Elated Paradigm Biopharmaceuticals's (ASX:PAR) Shareholders Feel About Its 365% Share Price Gain?

It hasn't been the best quarter for Paradigm Biopharmaceuticals Limited (ASX:PAR) shareholders, since the share price has fallen 12% in that time. … We'd be remiss not to mention the difference between Paradigm Biopharmaceuticals's total shareholder return (TSR) and its share price return. … We note that Paradigm Biopharmaceuticals's TSR, at 377% is higher than its share price return of 365%.

Simply Wall St -

What Did Paradigm Biopharmaceuticals Limited's (ASX:PAR) CEO Take Home Last Year?

See our latest analysis for Paradigm Biopharmaceuticals How Does Paul Rennie's Compensation Compare With Similar Sized Companies? … At the time of writing our data says that Paradigm Biopharmaceuticals Limited has a market cap of AU$286m, and is paying total annual CEO compensation of AU$573k. … ASX:PAR CEO Compensation, May 24th 2019 Is Paradigm Biopharmaceuticals Limited Growing?

Simply Wall St -

How Much Are Paradigm Biopharmaceuticals Limited (ASX:PAR) Insiders Spending On Buying Shares?

So before you buy or sell Paradigm Biopharmaceuticals Limited (ASX:PAR), you may well want to know whether insiders have been buying or selling. … Paradigm Biopharmaceuticals Insider Transactions Over The Last Year. … Even though the purchase was made at a significantly lower price than the recent price (AU$1.56), we still think insider buying is a positive

Simply Wall St -

Do Insiders Own Shares In Paradigm Biopharmaceuticals Limited (ASX:PAR)?

A look at the shareholders of Paradigm Biopharmaceuticals Limited (ASX:PAR) can tell us which group is most powerful. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … With a market capitalization of AU$267m, Paradigm Biopharmaceuticals is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Introducing Paradigm Biopharmaceuticals (ASX:PAR), The Stock That Soared 395% In The Last Three Years

One such superstar is Paradigm Biopharmaceuticals Limited (ASX:PAR), which saw its share price soar 395% in three years. … With just AU$2,688,306 worth of revenue in twelve months, we don't think the market considers Paradigm Biopharmaceuticals to have proven its business plan. … Given the share price has increased by a solid 70% per year, over 3 years, its fair to say investors remain excited about the future, despite the potential need for cash.

Simply Wall St -

How Paradigm Biopharmaceuticals Limited (ASX:PAR) Can Impact Your Portfolio Volatility

Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful. … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

Should You Be Concerned About Paradigm Biopharmaceuticals Limited's (ASX:PAR) Shareholders?

Today, I will be analyzing Paradigm Biopharmaceuticals Limited’s (ASX:PAR) recent ownership structure, an important but not-so-popular subject among individual investors. … Differences in ownership structure of companies can have a profound effect on how management's incentives are aligned with shareholder returns, and whether they adhere to corporate governance best practices. … ASX:PAR Ownership Summary July 17th 18

Simply Wall St -

Should You Have Paradigm Biopharmaceuticals Limited's (ASX:PAR) In Your Portfolio?

With a beta of 1.48, Paradigm Biopharmaceuticals is a stock that tends to experience more gains than the market during a growth phase and also a bigger reduction in value compared to the market during a broad downturn. … I test PAR’s ratio of fixed assets to total assets in order to determine how high the risk is associated with this type of constraint. … This outcome contradicts PAR’s current beta value which indicates an above-average volatility.

Simply Wall St -

Company Info

Description

Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable and tablet forms for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Details
Name: Paradigm Biopharmaceuticals Limited
PAR
Exchange: ASX
Founded: 2014
A$610,656,520
194,476,599
Website: http://www.paradigmbiopharma.com
Address: Paradigm Biopharmaceuticals Limited
500 Collins Street,
Level 15,
Melbourne,
Victoria, 3000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX PAR Ordinary Shares Australian Securities Exchange AU AUD 19. Aug 2015
OTCPK PBIG.F Ordinary Shares Pink Sheets LLC US USD 19. Aug 2015
CHIA PAR Ordinary Shares Chi-X Australia AU AUD 19. Aug 2015
Number of employees
Current staff
Staff numbers
0
Paradigm Biopharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:41
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2019/10/09
Last earnings filing: 2019/08/30
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.